MMC may not be needed post-PRK

Article

Mitomycin C (MMC) 0.01% may not be needed to prevent post wavefront-guided photorefractive keratectomy (PRK) haze in highly myopic patients, reveals a recent paper.

Mitomycin C (MMC) 0.01% may not be needed to prevent post wavefront-guided photorefractive keratectomy (PRK) haze in highly myopic patients, reveals a recent paper.

A double-masked, randomized, prospective trial, managed by Dr Elizabeth M. Hofmeister, Naval Medical Centre, San Diego, California, USA, involved 60, 30 and 15 second exposure of MMC on eyes with high myopia. One eye received MMC via a surgical sponge and the fellow eye received a placebo.

A four-month tapering postoperative topical steroid regimen was applied to all eyes. Preoperative measures included endothelial cell densities, haze scores, high- and low-contrast acuities and manifest refraction. The same measurements were also taken 1, 3, 6 and 12 months postoperatively.

Mean preoperative manifest refraction spherical equivalent was -5.98 dioptres and no eye developed more than trace haze. A significant difference in haze scores was discovered between MMC-treated eyes and untreated eyes at 1 and 3 months postoperatively, compared to no difference at 6 and 12 months.

Endothelial cell densities decreased in treated eyes and untreated eyes at all 3 exposures. However, all eyes returned to baseline by six months and there were no differences in acuities or refractions with or without MMC.

Overall, the team concluded there were no clinically significant differences in haze formation between MMC eyes and control eyes. This means MMC may not be required to stop haze after PRK.

Please visit the Journal of Cataract and Refractive Surgery for the abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.